

PX'THERAPEUTICS ANNOUNCES THE SUCCESSFUL COMPLETION OF RGP41 GMP MANUFACTURING FOR MYMETICS

Grenoble, France, and Epalinges, Switzerland, December 12th, 2017

PX'Therapeutics, a CDMO specializing in the development of recombinant proteins for human and animal health, is proud to announce the end of the rgp41 manufacturing campaign and batch certification for clinical application. This drug substance will be used by Mymetics to develop a new vaccine formulation, within the framework of the MACIVIVA project, sustained by the European Union's Horizon 2020 research and innovation program and the Swiss State Secretariat for Education, Research and Innovation (SERI) for the Swiss based consortium partners.

Rgp41 protein is one of the HIV-1 gp41 derived antigens constituting Mymetics' HIV-1 vaccine that is anchored to the membrane surface of the virosome particle, which acts as vaccine delivery vehicle for soliciting the immune system for inducing the production of protective serum and mucosal antibodies.

PX'Therapeutics and Mymetics joined forces several years ago to work on rgp41 protein design and development of the production and purification processes of the molecule. PX teams managed to develop an efficient, scalable and GMP-compliant process. A clinical batch was produced from a scale fermentation volume of 120 L to deliver a sufficient quantity for formulation studies and clinical trials.

Claire Untereiner, Chief Operating Officer of PX'Therapeutics, commented as follows: "We are so happy to see the progress made with this molecule and to be part of this fantastic project. MACIVIVA's objective, the development of cold-chain independent and virosome-based vaccines, responds to a real medical need, particularly in emerging countries, and is in line with PX'Therapeutics' mission, to support and accelerate the development of innovative medicines".

Sylvain Fleury, Chief Scientific Officer of Mymetics SA commented: "we are pleased that PX'Therapeutics could address many technical challenges related to the GMP development of the recombinant rgp41 protein and achieve a production yield superior to our expectations. With this rgp41, Mymetics will further pursue the development of its HIV-1 candidate vaccine, which could be administered through various immunization routes, as a standalone product or combined with viral vectors in a prime-boost approach".

About PX'Therapeutics

PX'Therapeutics is a Contract Development and Manufacturing Organization (CDMO) specializing in the development of biologics (proteins including antibodies and antibody fragments, cells, and micro-organisms), for research and clinical applications. With more than 1,000 projects implemented since its creation in 2000, PX'Therapeutics is recognized for its scientific expertise coupled with state-of-the-art GMP capacities, in addition to team flexibility and committed dedication to the success of customers' projects. Today, the company's mission is to accelerate the development of biologics thanks to a combination of services, from lead optimization and process development through to GMP manufacturing and CMC consulting.

More information on www.px-therapeutics.com

About Mymetics

Mymetics Corp. (MYMX) is a Swiss based biotechnology company, with a Research Lab in the Netherlands, focused on the development of next-generation preventative vaccines for life threatening and life disabling diseases. It currently has four vaccines in its pipeline: HIV-1/AIDS, intra-

nasal Influenza, Malaria, Chikungunya and the RSV vaccine. HIV, malaria and intra-nasal influenza vaccines have successfully finished Phase 1 clinical trials, while the others are in the pre-clinical phase.

Mymetics' core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Mymetics' vaccines are designed to induce protection against early transmission and infection, focusing on the mucosal immune response as a first-line defense, in combination with humoral and cellular immune responses as a second-line defense, which can be essential for the development of an effective vaccine.

Mymetics' unique approach is being validated through partnerships with leading pharmaceutical or research organizations, including previous projects with PATH-MVI and the Bill and Melinda Gates Foundation.

For further information, please visit www.mymetics.com.

About MACIVIVA

The MACIVIVA project is funded as part of Horizon 2020, the European Union research and innovation framework program and by the Swiss State Secretariat for Education, Research and Innovation (SERI) for the Swiss based consortium partners. The €8.4 million grants are funding the evaluation, development and manufacturing scale-up of thermostable and cold-chain independent nano-pharmaceutical virosome-based vaccine candidates.

Mymetics acts as coordinator and works with the consortium partners, Catalent UK Swindon Zydis Ltd, Chimera Biotec GmbH (Germany), Upperton Ltd. (UK) and Bachem AG (Switzerland).

This project is funded under the European Union's Horizon 2020 research and innovation programme under Grant Agreement No 646122.  More information: www.maciviva.com

Contacts

PX'Therapeutics

Claire Untereiner
Chief Operating Officer
7 parvis Louis Néel – CS20050 BHT52A
38040 Grenoble Cedex – FRANCE
Phone: +33 (0)4.38.02.36.50
Claire.untreiner@px-therapeutics.com

Mymetics

Ronald Kempers
CEO
Route de la Corniche 4
1066 Epalinges - Switzerland
Phone : +41 21 653 4535
info@mymetics.com